Spotlight on Antibodies

Biointron

Spotlight on Antibodies by Biointron is your go-to monthly podcast exploring the latest trends, breakthroughs, and challenges in the antibody industry. From cutting-edge technologies like high-throughput antibody discovery to insights on market shifts and regulatory updates, we bring you expert perspectives and actionable knowledge to stay ahead in this competitive field. Whether you're a biotech professional, researcher, or industry enthusiast, this podcast offers a perfect blend of education and industry updates, helping you stay informed and inspired to innovate.

  1. May 29

    Spotlight on Antibodies | Episode 17 | May 1 - 31, 2026

    Spotlight on Antibodies is a podcast from ⁠Biointron⁠, where we bring you the latest antibody industry trends. This month in May, we'll highlight the future of VHH technology, chemical conjugation in antibody therapeutics, and emerging trends in antibody characterization. References: https://www.tandfonline.com/doi/full/10.1080/19420862.2025.2516676https://academic.oup.com/peds/article/doi/10.1093/protein/gzaf010/8262225https://academic.oup.com/bioinformaticsadvances/article/4/1/vbae033/7623636https://www.nature.com/articles/s42003-026-09594-yhttps://pubs.acs.org/doi/10.1021/polymscitech.5c00080https://pmc.ncbi.nlm.nih.gov/articles/PMC12203927/https://link.springer.com/article/10.1186/s11671-025-04200-2https://pubs.acs.org/doi/full/10.1021/acs.bioconjchem.3c00040https://www.nature.com/articles/s41598-023-43431-0https://www.cell.com/cell-reports-methods/fulltext/S2667-2375(26)00116-5https://www.mdpi.com/1424-8247/16/2/291

    15 min

  2. May 1

    Spotlight on Antibodies | Episode 16 | April 1 - 30, 2026

    Spotlight on Antibodies is a podcast from ⁠Biointron⁠, where we bring you the latest antibody industry trends. This month, in April, we'll highlight ATP-dependent switch antibodies, the throughput-quality gap in antibody discovery, and multiple myeloma antibody treatments. References:    https://link.springer.com/article/10.1007/s40259-025-00752-yhttps://www.sciencedirect.com/science/article/pii/S221112472031531Xhttps://link.springer.com/article/10.1208/s12248-026-01238-7https://www.annalsofoncology.org/article/S0923-7534(25)03071-6/fulltexthttps://aacrjournals.org/cancerdiscovery/article/11/1/158/2793/Antibody-to-CD137-Activated-by-Extracellularhttps://link.springer.com/article/10.1208/s12248-026-01238-7https://jitc.bmj.com/content/14/1/e013397https://link.springer.com/article/10.1007/s40200-024-01386-7https://link.springer.com/article/10.1186/s13036-025-00513-zhttps://academic.oup.com/abt/article/6/1/13/6823522https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(24)02423-6/fulltext

    13 min

  3. Apr 2

    Spotlight on Antibodies | Episode 15 | March 1 - 31, 2026

    Spotlight on Antibodies is a podcast from ⁠Biointron⁠, where we bring you the latest antibody industry trends. This month in March, we'll highlight antibody allostery, trends in developability, and anti-IgE therapeutics.  References: https://www.sciencedirect.com/science/article/abs/pii/S0734975024001769https://www.tandfonline.com/doi/full/10.1080/19420862.2017.1367074#abstracthttps://www.mdpi.com/2304-8158/14/8/1360https://www.sciencedirect.com/science/article/pii/S002228362500381Xhttps://www.nature.com/articles/s41467-025-65666-3https://www.tandfonline.com/doi/full/10.1080/19420862.2023.2185924#abstracthttps://www.fiercebiotech.com/sponsored/why-early-developability-assessment-strategic-necessity-modern-antibody-discoveryhttps://www.tandfonline.com/doi/full/10.1080/19420862.2025.2562999https://www.tandfonline.com/doi/full/10.1080/19420862.2025.2593055%4010.1080/tfocoll.2023.0.issue-biologics-developabilityhttps://www.tandfonline.com/doi/full/10.1080/19420862.2026.2627669https://www.frontiersin.org/journals/allergy/articles/10.3389/falgy.2026.1759921/fullhttps://www.biospace.com/press-releases/poplar-therapeutics-closes-45-million-series-a-extension-to-advance-development-of-lead-program-phb-050-a-new-class-of-anti-ige-therapy-for-multiple-atopic-conditionshttps://excellergy.com/excellergy-to-be-acquired-by-novartis-for-up-to-usd-2-billion-to-advance-potentially-first-in-class-trifunctional-effector-cell-response-inhibitors/

    13 min

  4. Feb 27

    Spotlight on Antibodies | Episode 14 | February 1 - 28, 2026

    Spotlight on Antibodies is a podcast from ⁠Biointron⁠, where we bring you the latest antibody industry trends. This month in February, we'll highlight radioantibodies, antibody-cytokine fusion proteins, and conditionally active antibodies. References: https://www.mdpi.com/2072-6694/17/21/3412https://www.sciencedirect.com/science/article/abs/pii/S0001299896800201?via%3Dihubhttps://swissrockets.com/news/swiss-rockets-group-alloy-therapeutics-partner-to-advance-radioligand-therapeutics-in-oncologyhttps://www.northstarnm.com/convergent-therapeutics-and-northstar-medical-radioisotopes-announce-expanded-partnership-to-support-convergents-late-stage-alpha-emitting-radioantibody-program/https://www.businesswire.com/news/home/20250612596008/en/Debiopharm-and-Alkyon-Therapeutics-Announce-Research-Collaboration-to-Advance-the-Next-Generation-of-Radioligand-Therapieshttps://pmc.ncbi.nlm.nih.gov/articles/PMC6994257/https://www.tandfonline.com/doi/full/10.1080/19420862.2025.2590250https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1498697/fullhttps://www.sciencedirect.com/science/article/pii/S0305737225000593https://jitc.bmj.com/content/13/4/e010566https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1640427/fullhttps://www.sciencedirect.com/science/article/pii/S2468294224000170?via%3Dihubhttps://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3077https://pubs.acs.org/doi/10.1021/jacs.5c16108

    15 min

  5. Jan 30

    Spotlight on Antibodies | Episode 13 | January 1 - 31, 2026

    Spotlight on Antibodies is a podcast from ⁠Biointron⁠, where we bring you the latest antibody industry trends. This month in January, we'll do a deep dive into last year's novel antibody drugs, G protein-coupled receptors, and fusion proteins. References: https://www.biointron.com/antibody-industry-trends/q4-2025-biointron-antibody-industry-insights-report.htmlhttps://www.cell.com/trends/pharmacological-sciences/abstract/S0165-6147(25)00284-6https://firstwordpharma.com/story/7047344https://www.tandfonline.com/doi/10.1080/17460441.2023.2193389https://currentprotocols.onlinelibrary.wiley.com/doi/10.1002/cpz1.1061https://linkinghub.elsevier.com/retrieve/pii/S0165614721001899https://academic.oup.com/jimmunol/article/214/3/565/8052974https://www.nature.com/articles/s44386-025-00015-4https://doi.org/10.3389/fimmu.2025.1498697https://www.sciencedirect.com/science/article/pii/S2950588725000060

    16 min

  6. 12/31/2025

    Spotlight on Antibodies | Episode 12 | December 1 - 31, 2025

    Spotlight on Antibodies is a podcast from ⁠Biointron⁠, where we bring you the latest antibody industry trends. This December, we'll highlight the antibody startup ecosystem, microfluidic strategies driving next-generation antibody discovery, and the landscape of psoriasis treatment. References: https://www.mdpi.com/2079-6374/15/7/409https://www.tandfonline.com/doi/full/10.1080/19420862.2025.2597610?src=https://www.nature.com/articles/s41587-024-02346-5https://pubs.rsc.org/en/content/articlehtml/2025/lc/d5lc00340ghttps://www.sciencedirect.com/science/article/pii/S2667237524003242https://www.nature.com/articles/s41551-025-01411-xhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11417777/https://www.prnewswire.com/news-releases/chinas-first-domestic-il-23p19-monoclonal-antibody-innovents-pecondle-picankibart-injection-received-nmpa-approval-302627980.htmlhttps://www.nature.com/articles/d41586-025-02649-whttps://www.mdpi.com/1422-0067/26/19/9616

    14 min

  7. 12/01/2025

    Spotlight on Antibodies | Episode 11 | November 1 - 30, 2025

    Spotlight on Antibodies is a podcast from ⁠Biointron⁠, where we bring you the latest antibody industry trends. This November, we'll highlight how non-canonical antibodies are reshaping immunotherapy, combination antibody therapies, and T cell exhaustion. References: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1723343/fullhttps://www.tandfonline.com/doi/10.1080/19420862.2025.2583210#abstracthttps://www.cancertreatmentreviews.com/article/S0305-7372(15)00193-0/abstracthttps://link.springer.com/article/10.1186/s13045-023-01509-2https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1556245/fullhttps://link.springer.com/article/10.1186/s12879-025-11012-3https://www.sciencedirect.com/science/article/pii/S2274580724005934https://onlinelibrary.wiley.com/doi/10.1002/ctm2.70345https://www.pnas.org/doi/10.1073/pnas.2409564122https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1507501/fullhttps://www.nature.com/articles/s41577-019-0221-9https://www.sciencedirect.com/science/article/pii/S1074761325003711

    14 min

  8. 10/31/2025

    Spotlight on Antibodies | Episode 10 | October 1 - 31, 2025

    Spotlight on Antibodies is a podcast from ⁠Biointron⁠, where we bring you the latest antibody industry trends. This October, we'll highlight advances in antibody design with AI, crossing the BBB, and universal antibodies.  References: https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-025-00764-4https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1637602/fullhttps://pubs.acs.org/doi/10.1021/acs.bioconjchem.5c00379https://www.nature.com/articles/s41467-025-59447-1https://www.sciencedirect.com/science/article/pii/S0165614725001828https://pmc.ncbi.nlm.nih.gov/articles/PMC12306175/https://pubs.acs.org/doi/10.1021/acsami.4c18679https://www.nature.com/articles/s41590-025-02286-5https://www.science.org/doi/10.1126/sciadv.adx3505https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00481-5/abstracthttps://pubs.acs.org/doi/10.1021/acsnano.5c08128https://www.cell.com/cell/fulltext/S0092-8674(25)01032-3

    9 min
See All (17)

About

Spotlight on Antibodies by Biointron is your go-to monthly podcast exploring the latest trends, breakthroughs, and challenges in the antibody industry. From cutting-edge technologies like high-throughput antibody discovery to insights on market shifts and regulatory updates, we bring you expert perspectives and actionable knowledge to stay ahead in this competitive field. Whether you're a biotech professional, researcher, or industry enthusiast, this podcast offers a perfect blend of education and industry updates, helping you stay informed and inspired to innovate.

Information

  • Creator
    Biointron
  • Years Active
    2025 - 2026
  • Episodes
    17
  • Rating
    Clean
  • Copyright
    © Biointron
  • Show Website
    Spotlight on Antibodies

You Might Also Like